NCT05374512: A Study of Dato-DXd Versus Investigator’s Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Chemotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must not be candidates for PD-1/PD-L1 inhibitor therapy (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)
Exclusions: Patients with prior chemotherapy or targeted systemic therapy for metastatic or locally recurrent inoperable breast cancer; Patients with prior exposure to datopotamab deruxtecan/Dato-DXd/DS-1062a), or any treatment containing a chemotherapeutic agent targeting topoisomerase I (e.g. Irinotecan hydrochloride, Etirinotecan pegol, Enhertu/Trastuzumab deruxtecan) or TROP2-targeted therapy (e.g. Trodelvy/sacituzumab govitecan); Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease

Comments are closed.

Up ↑